-
Posted by
Two Blokes Jun 18 -
Filed in
Stock
-
3 views
Organon stock is deeply undervalued after a 70% decline and a sharp dividend cut, now trading at just 2.6x forward PE. Growth headwinds in established brands are offset by strong momentum in biosimilars and women's health, particularly Nexplanon. Management's focus has shifted to aggressive debt reduction, suspending shareholder rewards, which is the need of the hour.
